糖尿病性腎障害(Diabetic Nephropathy)治療薬のグローバル製品開発パイプライン動向

◆英語タイトル:Diabetic Nephropathy - Pipeline Review, H2 2014
◆商品コード:GMDHC5439IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2014年9月30日
◆ページ数:206
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Diabetic Nephropathy – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Diabetic Nephropathy – Pipeline Review, H2 2014’, provides an overview of the Diabetic Nephropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Nephropathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Nephropathy – Overview 10
Pipeline Products for Diabetic Nephropathy – Comparative Analysis 11
Diabetic Nephropathy – Therapeutics under Development by Companies 12
Diabetic Nephropathy – Therapeutics under Investigation by Universities/Institutes 16
Diabetic Nephropathy – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Diabetic Nephropathy – Products under Development by Companies 21
Diabetic Nephropathy – Products under Investigation by Universities/Institutes 24
Diabetic Nephropathy – Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Johnson & Johnson 26
Sanofi 27
AstraZeneca PLC 28
Eli Lilly and Company 29
GlaxoSmithKline plc 30
Gilead Sciences, Inc. 31
Daiichi Sankyo Company, Limited 32
Astellas Pharma Inc. 33
Chong Kun Dang Pharmaceutical Corp. 34
InterMune, Inc. 35
Mitsubishi Tanabe Pharma Corporation 36
Pfizer Inc. 37
NephroGenex, Inc. 38
Shire Plc 39
Bayer AG 40
Mesoblast Limited 41
Jazz Pharmaceuticals plc 42
Torrent Pharmaceuticals Limited 43
Dong Wha Pharma Co., Ltd. 44
Galectin Therapeutics, Inc. 45
PhytoHealth Corporation 46
DiaMedica Inc. 47
Angelini Group 48
IMMD Inc. 49
GenKyoTex S.A. 50
Concert Pharmaceuticals, Inc. 51
Noxxon Pharma AG 52
Intercept Pharmaceuticals, Inc. 53
Omeros Corporation 54
ChemoCentryx, Inc. 55
Glucox Biotech AB 56
GNI Group Ltd. 57
OncoImmune, Inc. 58
Cellmid Limited 59
Serodus ASA 60
Islet Sciences, Inc. 61
AbbVie Inc. 62
Inventiva SAS 63
Mallinckrodt plc 64
Diabetic Nephropathy – Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Target 66
Assessment by Mechanism of Action 70
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78
canagliflozin – Drug Profile 78
atrasentan hydrochloride – Drug Profile 80
Pyridoxamine Dihydrochloride – Drug Profile 81
pirfenidone – Drug Profile 82
baricitinib – Drug Profile 84
SER-150 – Drug Profile 86
emapticap pegol – Drug Profile 87
IMD-1041 – Drug Profile 89
CS-3150 – Drug Profile 90
DW-1029M – Drug Profile 91
GKT-137831 – Drug Profile 92
PF-00489791 – Drug Profile 93
CCX-140 – Drug Profile 94
bindarit – Drug Profile 96
probucol – Drug Profile 98
PF-04634817 – Drug Profile 99
GLY-230 – Drug Profile 100
corticotropin – Drug Profile 102
BMS-813160 – Drug Profile 104
CTP-499 – Drug Profile 105
MT-3995 – Drug Profile 107
finerenone – Drug Profile 108
PHN-033 – Drug Profile 109
CKD-322 – Drug Profile 110
Allogeneic Mesenchymal Precursor Cells for Diabetic Nephropathy – Drug Profile 111
GS-4997 – Drug Profile 113
Small Molecule to Inhibit Xanthine Oxidase for Diabetic Nephropathy – Drug Profile 114
DM-199 – Drug Profile 115
MT-3995 – Drug Profile 117
SHP-627 – Drug Profile 118
ASP-8232 – Drug Profile 119
ASP-7657 – Drug Profile 120
pirfenidone – Drug Profile 121
DT-23552 – Drug Profile 122
INT-767 – Drug Profile 123
A-717 – Drug Profile 125
GR-MD-02 – Drug Profile 126
hu-91 – Drug Profile 128
Oligotide – Drug Profile 130
GKT-136901 – Drug Profile 132
Small Molecule to Inhibit NOX 1 and 4 – Drug Profile 134
Cyndacel-M – Drug Profile 135
Monoclonal Antibody to Target HPTPbeta for Diabetic Nephropathy – Drug Profile 136
Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders – Drug Profile 137
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders – Drug Profile 138
MG-132 – Drug Profile 139
GW-610742 – Drug Profile 140
TRC-120038 – Drug Profile 142
JNJ-39933673 – Drug Profile 143
11-RVIVIT – Drug Profile 144
Nephrilin – Drug Profile 145
DCB-DN1 – Drug Profile 146
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders – Drug Profile 147
SP-20202 – Drug Profile 149
OX-029 – Drug Profile 150
Drug for Diabetic Nephropathy – Drug Profile 151
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy – Drug Profile 152
Small Molecules for Diabetic Nephropathy – Drug Profile 153
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications – Drug Profile 154
NP-04 – Drug Profile 156
Small Molecules for Diabetic Nephropathy – Drug Profile 157
Diabetic Nephropathy – Recent Pipeline Updates 158
Diabetic Nephropathy – Dormant Projects 191
Diabetic Nephropathy – Discontinued Products 192
Diabetic Nephropathy – Product Development Milestones 193
Featured News & Press Releases 193
Appendix 201
Methodology 201
Coverage 201
Secondary Research 201
Primary Research 201
Expert Panel Validation 201
Contact Us 202
Disclaimer 202



【掲載企業】

Bristol-Myers Squibb Company
Johnson & Johnson
Sanofi
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Gilead Sciences, Inc.
Daiichi Sankyo Company, Limited
Astellas Pharma Inc.
Chong Kun Dang Pharmaceutical Corp.
InterMune, Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
NephroGenex, Inc.
Shire Plc
Bayer AG
Mesoblast Limited
Jazz Pharmaceuticals plc
Torrent Pharmaceuticals Limited
Dong Wha Pharma Co., Ltd.
Galectin Therapeutics, Inc.
PhytoHealth Corporation
DiaMedica Inc.
Angelini Group
IMMD Inc.
GenKyoTex S.A.
Concert Pharmaceuticals, Inc.
Noxxon Pharma AG
Intercept Pharmaceuticals, Inc.
Omeros Corporation
ChemoCentryx, Inc.
Glucox Biotech AB
GNI Group Ltd.
OncoImmune, Inc.
Cellmid Limited
Serodus ASA
Islet Sciences, Inc.
AbbVie Inc.
Inventiva SAS
Mallinckrodt plc

【レポートのキーワード】

糖尿病性腎障害(Diabetic Nephropathy)、治療薬、薬剤、開発開発、製薬企業、製品パイプライン

★調査レポート[糖尿病性腎障害(Diabetic Nephropathy)治療薬のグローバル製品開発パイプライン動向] (コード:GMDHC5439IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[糖尿病性腎障害(Diabetic Nephropathy)治療薬のグローバル製品開発パイプライン動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆